je.st

Home › expanding

Tag: expanding

Post Fixing Resin produces expanding, fast-setting foam.

2015-05-18 14:31:06| Industrial Newsroom - All News for Today

Without requiring special tools or water, Sika® Post Fix 2-part, pre-proportioned polyurethane resin produces expanding foam when mixed. Set time is 3 min for this mix-in-the-bag backfill, which is suited for securing wood, PVC, steel, or concrete in-ground posts and hardens completely in 2 hr. Once mixed and in foam state, product is inert and will not leach into soil. Also, chemical formulation will not harm soil or surrounding environment, and excess material can be cut away with knife.

Tags: post produces expanding foam

Focus On Expanding Store Base Earns Whole Foods A Bullish Thesis

2015-05-16 22:51:31| Grocery - Topix.net

I reiterate my bullish stance on Whole Foods Market ; the company reported healthy 2QFY15 results, which were strongly backed by the active execution of its well thought-out strategic growth initiatives. Moving ahead, WFM will continue to grow its existing store base to improve its attractiveness for customers seeking quality organic food at low prices.

Tags: store base focus foods

Toronto expanding plastic recycling program

2015-05-16 18:15:46| Canadian Plastics Headlines

Blue Bin recycling program will increase TO's diversion rate by an expected 2%. The post Toronto expanding plastic recycling program appeared first on Canadian Plastics.

Tags: program plastic toronto expanding

2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Mercks Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA (pembrolizumab) to be Presented

2015-05-13 23:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. New Findings Show Anti-tumor Activity of KEYTRUDA in Five Additional Cancers: Colorectal, Esophageal, Ovarian, Renal Cell Carcinoma and Small-Cell Lung Cancer First-Time Presentations of DNA Mismatch Repair Deficiency Data in Colorectal and other Cancers and Nanostring RNA Data in Melanoma, Head and Neck and Gastric Cancers Industry-leading Number of PD-1 Clinical Trials Resulting in Growing Body of Data for KEYTRUDA across 13 Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new investigational data in 10 different types of cancer from the companys immuno-oncology development program evaluating its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 29 June 2, 2015. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to data research program